publication date: Mar. 16, 2018
Conversation with the Cancer Letter
Basch: Patient-reported outcomes data can make cancer drugs safer, more tolerable
Director of the Cancer Outcomes Research Program, professor of medicine and public health at the UNC Lineberger Comprehensive Cancer Center.
Fifteen years ago, when Ethan Basch started developing measures for aggregating patient-reported outcomes, many of his colleagues in oncology saw no promise in this enterprise.
“We conducted cooperative group studies and showed that the vast majority of patients were willing and able to self-report even when extremely ill or close to death or hospice,” said Basch, director of the Cancer Outcomes Research Program and professor of medicine and public health at the UNC Lineberger Comprehensive Cancer Center.
“These data were useful for responding to my skeptical colleagues who asserted, ‘We understand our patients well, so we don’t need them to provide their own information. We know what’s going on with them, we talk to them all the time. And patients probably aren’t willing or able to report their toxicities during trials, they have a lot going on.’ But our data showed those assertions were not true.”
Now, NCI plans to commit $3.25 million in fiscal year 2018 to fund three to five awards focused on studying patient adverse event data to better understand how patients are tolerating cancer treatments—as part of the institute’s PRO-CTCAE platform, also known as the Patient-Reported Outcomes version of the Common Terminology Criteria … Continue reading Basch: Patient-reported outcomes data can make cancer drugs safer, more tolerable
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.